Fig 1: DR5 mediates the inhibitory effect of TRAIL on platelet-induced tumor cell invasion. (a,b) DR4 and DR5 expression were detected by ow cytometry and real-time polymerase chain reaction in platelets. (c) Detection of TRAIL receptors DR4/DR5 in platelets by western blot. (d,e) Invasive abilities of HT29 and HCT116 cell lines were determined by transwell assay in the TRAIL, platelet, platelet + TRAIL, platelet+DR4, and platelet+DR5 groups. (Crystal violet stain). *P < 0.05 compared with control group. Scale bars = 200 µm. (f,g) VEGF and TGF-β1 were detected by ELISA. Data are shown as mean ± standard error. *P < 0.05 compared with PBS group. n = 6 per group. con: control, GAPDH, glyceraldehyde 3-phosphate dehydrogenase, TRAIL: tumor necrosis factor-related apoptosis-inducing ligand, PBS: phosphate-buffered saline.
Supplier Page from Abcam for Anti-DR5 antibody